Document:

Form of Deferred Stock Agreement

 Exhibit 10.34 
 DEFERRED STOCK AGREEMENT 
 For [Number of shares] Restricted Stock Units 
 Issued Pursuant To The Cooper Companies, Inc. 
 2007 Long Term Incentive Plan (“The Plan”) 
 THIS CERTIFIES that on [date of grant] [Name] (the “Holder”) was
granted [Number of shares ([# of shares])] shares of the common stock, par value $.10 per share, of The Cooper Companies, Inc. (the “Company”) on a deferred basis and upon and subject to the following terms and conditions (the
“Deferred Stock”). 
 Unless otherwise indicated herein to the contrary, capitalized terms used in this Deferred Stock Agreement
shall have the same meanings as set forth in the Plan. 
 1. Deferred Stock. Subject to the terms of this Agreement and the Plan, Holder is hereby
awarded the right to receive the Deferred Stock as it vests as provided in Section 3 hereof. Unless and until the Shares are actually issued and delivered to the Holder, the Holder shall not by reason of being granted the Deferred Stock be
deemed to be a shareholder of the Company. Accordingly, the Holder shall not have any rights to vote any Shares subject to the Deferred Stock, or to receive dividends or any other rights of a shareholder until such Shares have been issued to the
Holder. 
 2. Shares. Once vested the Company shall cause that number of Shares equal to the vested portion of the Deferred Stock to either
(i) be issued and a stock certificate or certificates representing the Deferred Stock to be registered in the Holder’s name, or (ii) held in book entry form. 
 3. Vesting. The Deferred Stock will vest as follows: 
 (a) one-fourth shall vest on
January     , [15 months from date of grant]; 
 (b) one-fourth shall vest on January
    , [27 months from date of grant]; 
 (c) one-fourth shall vest on January
    , [39 months from date of grant]; 
 (d) one-fourth shall vest on January
    , [51 months from date of grant]. 
 4. Termination of Employment. In the event that Holder ceases to be employed by or
a consultant of the Company any Deferred Stock which has not yet vested shall be forfeited and cancelled, and Holder shall have no further right, title or interest with respect to such Deferred Stock. 
 5. Limit on Transfer. Holder may not sell, transfer, pledge or assign the Deferred Stock. Once the Deferred Stock becomes vested pursuant to Section 3
hereof, Holder shall have full ownership rights with respect all Shares delivered upon satisfaction of Holder’s Deferred Stock rights. 
 6.
Representations. The Committee may require Holder to represent to and agree with the Company in writing that Holder is acquiring the Shares for investment purposes and without a view to distribution thereof. The Company may condition the
delivery of the Deferred Stock upon the listing, registration or qualification of the Shares upon a securities exchange or under applicable securities laws. The Shares shall be subject to such stock transfer orders and other restrictions as the
Committee may deem advisable under rules, regulations and other requirements of the Securities and Exchange Commission, any stock exchange upon which the Stock is then listed and any applicable Federal or state securities law. The Company may cause
a legend to be put on each certificate representing Shares to reflect any of the provisions of this Section 6. 
  

 1 

 7. Continuation of Employment not Implied. Nothing contained in the Plan or this Agreement shall confer upon
Holder the right to continue as an employee or consultant of the Company or one of its affiliates, nor shall be interpreted to interfere with or limit in any way the right of the Company to terminate Holder’s employment or consultancy at any
time, with or without Cause. 
 Nothing contained in the Plan or this Agreement shall form part of the Employee’s entitlement to
remuneration and benefits in terms of his or her employment or affect the Employee’s terms and conditions of employment. 
 8. Merger,
Reorganization, Etc. In the event of any merger, reorganization, consolidation, recapitalization, stock dividend, stock split or other such change in corporate structure affecting the Deferred Stock, an equitable adjustment shall be made in the
number of Shares subject to the Deferred Stock; provided that the number of Shares of Deferred Stock shall always be a whole number. 
 9.
Withholding. The Company will deduct and withhold Shares otherwise to be delivered as Deferred Stock with a Fair Market Value equal to the minimum amount of applicable tax withholding arising from the receipt or vesting of the Deferred Stock.

 10. Amendments. The Board, with the consent of Holder, may amend at any time or from time to time the terms and conditions of this Deferred Stock
Agreement. 
 11. Data Protection and Personal Data. The Holder acknowledges and consents to the collection, use, processing and transfer of personal
data as described in this paragraph. The Company, and any Subsidiary or any Affiliate, may hold certain personal information regarding Holder, including Holder’s name, home address and telephone number, date of birth, social security number or
other employee tax identification number, salary, nationality, job title, any shares of stock awarded, cancelled, purchased, vested, unvested or outstanding in Holder’s favor, for the purpose of managing and administering the Plan
(“Data”). The Company, and any Subsidiary or any Affiliate, will transfer Data to any third parties assisting the Company, Subsidiary or Affiliate in the implementation, administration and management of the Plan. These recipients may be
located in the European Economic Area, or elsewhere, such as the United States. Holder authorizes them to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing
Holder’s participation in the Plan, including any requisite transfer of such Data as may be required for the administration of the Plan and/or the subsequent holding of shares of stock on Holder’s behalf to a broker or other third party
with whom Holder may elect to deposit any shares of stock acquired pursuant to the Plan. Holder may, at any time, review Data, require any necessary amendments to it or withdraw the consent herein in writing by contacting the Company and its
Subsidiaries or Affiliates; however, withdrawing the consent may affect Holder’s ability to participate in the Plan. 
 By signing this
Agreement, the Employee acknowledges and agrees that: 
  

	 	a.	the Company and any group companies or affiliates are permitted to hold and process personal (and sensitive) information and data about the Employee as part of their personnel and
other business records and may use such information in the course of its business; 

  

	 	b.	they may disclose such information to third parties, including where they are situated outside the European Economic Area, in the event that such disclosure is in their view
required for the proper conduct of their business; and 

  

	 	c.	this paragraph applies to information held, used or disclosed in any medium. 

 12. Notices. Any notice which either party hereto may be required or permitted to give to the other shall be in writing, and may be delivered personally or by mail, postage prepaid, addressed as follows: to the Company or any officer
of the Company or the Committee or any member thereof, at the Company’s 

  

 2 

 
offices at 6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588, or at such other address as the Company, or any other such person, by notice to Holder
may designate from time to time, and to Holder at Holder’s address as set forth below, or such other address as Holder by notice to the Company may designate in writing from time to time. Notices shall be effective upon receipt. 
 13. Governing Law. This Agreement shall be governed by the laws of the State of California, except to the extent preempted by Federal law. 
 14. Incorporation of the Plan; Interpretations. This Agreement is entered into pursuant to, and is subject to all of the terms and conditions of the Plan, the
terms, conditions and definitions of which are hereby incorporated as though set forth at length, and the receipt of a copy of which Holder hereby acknowledges by his signature below. A determination by the Committee as to any questions, which may
arise with respect to the interpretation of this Agreement or the Plan, shall be final. The Committee may authorize and establish such rules, regulations and revisions thereof not inconsistent with the provisions of the Plan, as it may deem
advisable. 
 15. Miscellaneous. The grant of Deferred Stock under the Plan is a one-time benefit and does not create any contractual or other right
to receive a grant of deferred stock or benefits in lieu of deferred stock in the future. Future grants of deferred stock, if any, will be at the sole discretion of the Company, including, but not limited to, the timing of the grant, the number of
shares of deferred stock, and vesting provisions. 
 The Deferred Stock and this Deferred Stock Agreement are issued pursuant to, and are
subject to all of the terms and conditions of, the Plan, the terms, conditions and definitions of which are hereby incorporated as though set forth at length, and the receipt of a copy of which the Holder hereby acknowledges by signing below. A
determination by the Committee as to any questions which may arise with respect to the interpretation of the provisions of the Deferred Stock or of the Plan shall be final. The Committee may authorize and establish such rules, regulations and
revisions thereof not inconsistent with the provisions of the Plan, as it may deem advisable. 
 ~ Signature Page Follows ~ 
  

 3 

 WITNESS the signatures of the Company’s duly authorized officers and the Holder. 
  

			
	THE COOPER COMPANIES, INC.
		
	By:	 	  

		 	Carol R. Kaufman
		 	Sr. Vice President of Legal Affairs,
		 	Secretary and Chief Administrative Officer

  

			
	ATTEST:
		
	By:	 	  

		 	Daniel G. McBride
		 	Vice President and General Counsel
	
	ACCEPTED:
		
	By:	 	  

		 	[name]
		 	[Address 1]
		 	[Address 2]

  

 4Amended and Restated Employment Agreement

 EXHIBIT 10.1 
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
 This Amended and Restated Employment Agreement (this
“Agreement”) is made as of December 19, 2007, by and between Pro-Pharmaceuticals (“Pro-Pharmaceuticals”), of 7 Wells Avenue, Suite 34, Newton, Massachusetts, 02459 and Theodore D. Zucconi Ph.D. (“Zucconi” or
“Employee”), of 3006 E. Dry Creek Road, Phoenix, Arizona, 85048. 
 A. Pro-Pharmaceuticals is engaged in the business of
biotechnology drug development. Zucconi will primarily perform the job duties at the following location: 7 Wells Avenue, Suite 34, Newton, MA. 
 B. Pro-Pharmaceuticals desires to have the services of Zucconi. 
 C. Zucconi is willing to be employed by Pro-Pharmaceuticals.

 D. Pro-Pharmaceuticals and Zucconi desire to amend and restate the Employment Agreement between them effective as of October 1, 2007
(the “Effective Date”). 
 Therefore, the parties agree as follows: 
 1. EMPLOYMENT. Zucconi agrees to be employed by Pro-Pharmaceuticals as President and serve as a member of the Board of Directors. Zucconi will provide to Pro-Pharmaceuticals the following services: general
duties of a President, including but not limited to: hiring and dismissal of employees, salary and compensation for all employees and consultants; approval of all finance, licensing, partnerships, and other corporate activities such as press
releases, mergers, acquisitions and/or divestitures. Zucconi accepts and agrees to such employment, and agrees to be subject to the supervision, and approval of Pro-Pharmaceutical’s Board of Directors (BOD) and Chief Executive Officer (CEO).
Zucconi will also perform (i) such other duties as are customarily performed by a President in a similar position, and (ii) such other and unrelated services and duties as may be assigned to Zucconi from time to time by
Pro-Pharmaceutical’s BOD and/or the CEO. 
 Zucconi will provide Pro-Pharmaceuticals with all information, suggestions, and
recommendations regarding Pro-Pharmaceuticals’ business, of which Zucconi has knowledge that will be of benefit to Pro-Pharmaceuticals. 
 2. BEST
EFFORTS OF EMPLOYEE. Zucconi agrees to perform faithfully, industriously, and to the best of Zucconi’s ability, experience, and talents, all of the duties that may be required by the express and implicit terms of this Agreement, to the
reasonable satisfaction of Pro-Pharmaceuticals. Such duties shall be provided at such place(s) as the needs, business, or opportunities of Pro-Pharmaceuticals may require from time to time. Zucconi shall observe all Company rules and policies,
including such policies as amended from time to time. 
 3. COMPENSATION OF EMPLOYEE. 
 A. As compensation for the services provided by Zucconi under this Agreement for the 2007 calendar year, Pro-Pharmaceuticals will pay Zucconi a monthly
salary of $9,167, payable in accordance with Pro-Pharmaceuticals’ usual payroll procedures and subject to reduction for the applicable 

 
withholding and payroll taxes. 
 B. As
compensation for the services provided by Zucconi under this Agreement beginning January 1, 2008, Pro-Pharmaceuticals will pay Zucconi an annual salary of $220,000 payable in accordance with Pro-Pharmaceuticals’ usual payroll procedures.
Zucconi, however, agrees that 50% of his annual salary payable in 2008 will be deferred and paid on or before October 1, 2008. Zucconi will receive monthly compensation of $9,167 in 2008, subject to reduction for the applicable withholdings and
payroll taxes, payable on the Company’s regular payroll dates. Pro-Pharmaceuticals shall also pay a cash bonus to Zucconi in the amount of $27,500 on or before June 1, 2008, which shall be payable in cash and in accordance with
Pro-Pharmaceuticals’ usual payroll procedures. Zucconi’s salary will be adjusted proportionately to the adjustments for other executives. 
 C. Zucconi shall be entitled to the following additional benefits: 
 (i) Reimbursement of relocation costs not to exceed $54,000 in
total; 
 (ii) Fourteen round trip single passenger aircraft tickets (by coach) per a year between Massachusetts and Phoenix, Arizona which
may be used by either Zucconi or his spouse; 
 (iii) A grant to be made prior to December 31, 2007 of stock options, which shall
contain a “cashless” exercise provision, for 200,000 shares of Pro-Pharmaceuticals common stock as an incentive to accept employment with Pro-Pharmaceuticals. The exercise price shall equal the fair market value of Pro-Pharmaceuticals
common stock on the date of grant of such stock options; 
 (iv) A grant of stock options, which shall contain a “cashless”
exercise provision, for 10,000 shares of Pro-Pharmaceuticals common stock per $1 million of financing received by Pro-Pharmaceuticals from sources identified by Zucconi and not from sources, or their successors, previously identified by
Pro-Pharmaceuticals. The exercise price shall equal the fair market value of Pro-Pharmaceuticals common stock on the date of grant of such stock options; 
 (v) Pro-Pharmaceuticals shall pay a cash bonus to Zucconi in the event a partnership or joint venture is formed or reached with another company with upfront fees and milestone payments in excess of $20 million in
accordance with Pro-Pharmaceuticals’ usual payroll procedures. The amount of the cash bonus payable to Zucconi shall equal 1% of the upfront fees and milestone payments which shall be payable within twenty (20) business days of receipt by
Pro-Pharmaceuticals of the upfront fees and milestone payments; 
 (vi) A grant of stock options, which shall contain a “cashless”
exercise provision, for 100,000 shares of Pro-Pharmaceuticals common stock in the event the closing price of Pro-Pharmaceuticals’ common stock exceeds $5 per a share for twenty (20) consecutive trading days prior to October 31, 2008.
The exercise price shall equal the fair market value of Pro-Pharmaceuticals common stock on the date of grant of such stock options; 
 The stock options
granted to Zucconi pursuant to sections (iii), (iv), and (vi) of this Section 3 shall (a) be fully vested on the date of grant, (b) expire on the fifth anniversary of the date of grant, and (c) be exercisable during the
5-year term whether or not Zucconi is then employed by Pro-Pharmaceuticals or this agreement has terminated. 
 4. PERSONAL TIME OFF. Zucconi shall be
entitled to four (4) weeks of paid Personal Time Off (PTO), pro-rated on a monthly basis. Such PTO must be taken at a time mutually convenient to Pro-Pharmaceuticals and Zucconi. Accrued vacation will be paid in accordance with MA state law and
Pro- 

 
Pharmaceuticals customary procedures. Unpaid time off will be by mutual agreement. 
 5. BENEFITS. The Employee will be entitled (i) to insurance and other benefits commensurate with the Employee’s position in accordance with the Company’s standard employee benefits policies as in
effect from time to time; (ii) to participate in the Company’s 401(k) plan with an employer match percentage as in effect from time to time; and (iii) four (4) weeks PTO annually, pro-rated on a monthly basis, and customary MA
holidays. 
 To the extent the Company maintains insurance with respect to (i) directors’ and officers’ liability,
(ii) errors and omissions and (iii) general liability insurance, the Employee shall be covered by such insurance to the same extent as other senior executives and directors of the Company. 
 6. EXPENSE REIMBURSEMENT. Pro-Pharmaceuticals will reimburse Zucconi for expenses incurred by Zucconi to conduct company business. This will be in accordance with
Pro-Pharmaceuticals policies in effect. 
 7. TERM/TERMINATION. Zucconi’s employment under this Agreement shall be for one (1) year,
beginning on October 01, 2007. This Agreement may be terminated by Pro-Pharmaceuticals upon 30 days written notice and by Zucconi upon 30 days written notice. Upon termination of this Agreement, payments under this paragraph shall cease,
provided, however, that Zucconi shall be entitled to deferred payments, if any, for the contract (maximum three months salary) and performance bonuses that occurred during employment and for which Zucconi has not yet been paid, unless Zucconi is in
violation of this Agreement. The compensation paid under this Agreement shall be Zucconi’s exclusive remedy. 
 The Employee
acknowledges and agrees that his employment by the Company is on an “at will” basis, meaning that either the Company or the Employee may terminate the employment at any time, without or without cause. 
 In the event the employment of the Employee is terminated by the Company “without cause” the Employee shall be entitled to severance as
follows: 
 (i) if termination occurs within six (6) months after the Effective Date, the Employee shall be paid Base Salary for one
month; provided however, that the Company may terminate the employment of the Employee within sixty (60) days after the Effective Date, with or without cause, and shall not be obligated to pay severance if termination occurs during such 60-day
period; 
 (ii) if termination occurs more than six (6) months after the Effective Date and before the first anniversary of the Effective
Date, the Employee shall be paid Base Salary for three (3) months; 
 (iii) the Employee shall be reimbursed for all expenses pursuant to
Section 6 incurred through the date of employment termination; 
 (vi) the Employee shall continue to have during such post-employment
period two (2) months of benefits, to the extent permitted by law, to which he was entitled pursuant to Section 5 hereof while he was employed by the Company. 
 8. CONFLICTING EMPLOYMENT. The Employee agrees that, during the term of the Employee’s employment with the Company, Employee will not engage in other employment, occupation, consulting, or other business
activity related to any biotech or pharmaceutical company business in which the Company is now involved—biotechnology drug development. 

 9. CONFIDENTIALITY. Zucconi recognizes that Pro-Pharmaceuticals has and will have information regarding the
following: drug development, FDA trials, and other vital information items (collectively, “Information”), which are valuable, special and unique assets of Pro-Pharmaceuticals. Zucconi will protect the Information and treat it as strictly
confidential as acknowledged in the Confidentiality Agreement executed by Zucconi and Pro-Pharmaceuticals, July 11, 2007. The confidentiality provisions of this Agreement shall remain in full force and effect for three (3) years following
the effective date of this Agreement. 
 10. COMPLIANCE WITH EMPLOYER’S RULES. Zucconi agrees to comply with all of the rules and regulations of
Pro-Pharmaceuticals and as amended from time to time. 
 11. RETURN OF PROPERTY. Upon termination of this Agreement and at the time of leaving the
employ of the Company, Zucconi shall deliver to Pro-Pharmaceuticals (and will not keep in Zucconi’s possession or deliver to anyone else) all devices, records, data, notes, reports, proposals, lists, correspondence, keys, specifications,
drawings, blueprints, sketches, materials, equipment, other documents or property, or reproductions of any of the aforementioned items, containing Confidential Information or otherwise belonging to the Company, its successors or assigns, whether
prepared by Zucconi or supplied to Zucconi by the Company. 
 12. INVENTIONS. 
 (a) Inventions Retained and Licensed. Attached hereto, as Exhibit A, is a list describing all ideas, processes, trademarks, service marks,
inventions, designs, technologies, computer hardware or software, original works of authorship, formulas, discoveries, patents, copyrights, copyrightable works, products, marketing and business ideas, and all improvements, know-how, data, rights,
and claims related to the foregoing, whether or not patentable, registrable or copyrightable, which were conceived, developed or created by the Employee prior to Employee’s employment or first contact with the Company (collectively referred to
as “Prior Inventions”), (A) which belong to the Employee, (B) which relate to the Company’s current or contemplated business, products or research and development, and (C) which are not assigned to the Company
hereunder. If there is no Exhibit A or no items thereon, the Employee represents that there are no such Prior Inventions. If in the course of Employee’s employment with the Company, the Employee incorporates or embodies into a Company
product, service or process a Prior Invention owned by the Employee or in which the Employee has an interest, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license to make, have made,
modify, use and sell such Prior Invention as part of or in connection with such product, service or process. 
 (b) Assignment of
Intellectual Property Items. The Employee agrees that Employee will promptly make full written disclosure to the Company and will hold in trust for the sole right and benefit of the Company, and the Employee hereby assigns to the Company, or its
designee, all of the Employee’s right, title and interest in and to any and all ideas, processes, trademarks, service marks, inventions, designs, technologies, computer hardware or software, original works of authorship, formulas, discoveries,
patents, copyrights, copyrightable works, products, marketing and business ideas, and all improvements, know-how, data, rights, and claims related to the foregoing, whether or not patentable, registrable or copyrightable, which the Employee may on
or after the Effective Date, solely or jointly with others conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice, during the period of time the Employee is in the employ of the Company (collectively
referred to as “Intellectual Property Items”); and the Employee further agrees that the foregoing shall also apply to Intellectual Property Items which relate to the business of the Company or to the Company’s anticipated
business as of the end of the Employee’s employment and which are conceived, developed, or reduced to 

 
practice during a period of one year after the end of such employment. Without limiting the foregoing, the Employee further acknowledges that all original
works of authorship which are made by the Employee (solely or jointly with others) within the scope of the Employee’s employment and which are protectable by copyright are works made for hire as that term is defined in the United States
Copyright Act. 
 (c) Maintenance of Records. The Employee agrees to keep and maintain adequate and current written records of all
Intellectual Property Items made by the Employee (solely or jointly with others) during the term of the Employee’s employment with the Company. The records will be in the form of notes, sketches, drawings, and any other format that may be
specified by the Company. The records will be available to, and remain the sole property of, the Company at all times. 
 (d) Patent and
Copyright Registrations. The Employee agrees to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the Intellectual Property Items and any copyrights, patents, mask work
rights or other intellectual property rights relating thereto in any and all countries, including the disclosure to the Company of all pertinent information and data with respect thereto and the execution of all applications, specifications, oaths,
assignments and all other instruments which the Company shall deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and exclusive rights, title and
interest in and to such Intellectual Property Items, and any copyrights, patents, mask work rights or other intellectual property rights relating thereto. 
 (e) No Use of Name. The Employee shall not at any time use the Company’s name or any of the Company trademark(s) or trade name(s) in any advertising or publicity without the prior written consent of the
Company. 
 13. NON-SOLICITATION. The Employee agrees that Employee shall not during the Employee’s employment or other involvement with the
Company and for a period of twelve (12) months immediately following the termination of the Employee’s employment with the Company for any reason, whether with or without cause, (i) either directly or indirectly solicit or take away,
or attempt to solicit or take away employees of the Company, either for the Employee’s own business or for any other person or entity, or (ii) either directly or indirectly recruit, solicit or otherwise induce or influence any proprietor,
partner, stockholder, lender, director, officer, employee, sales agent, joint venturer, investor, lessor, supplier, customer, agent, representative or any other person who has a business relationship with the Company to discontinue, reduce or modify
such employment, agency or business relationship with the Company. 
 14. COVENANTS AGAINST COMPETITION. 
 (a) Definitions. For the purposes of this Section: 
 (i) “Competing Product” means any product, process, or service of any person or organization other than the Company, in existence or under development (A) which is identical to, substantially the
same as, or an adequate substitute for any product, process, or service of the Company, in existence or under development, based on any patent or patent application (provisional or otherwise) which is owned by or licensed to the Company, or other
intellectual property of the Company about which the Employee acquires Confidential Information, and (B) which is (or could reasonably be anticipated to be) marketed or distributed in such a manner and in such a geographic area as to actually
compete with such product, process or service of the Company. 
 (ii) “Competing Organization” means any
person or organization, including the 

 
Employee, engaged in, or about to become engaged in, research on or the acquisition, development, production, distribution, marketing, or providing of a
Competing Product. 
 (b) Non-Competition. As a material inducement to the Company to employ or continue the employment of the
Employee, and in order to protect the Company’s Confidential Information and good will, the Employee agrees to the following stipulations: 
 (i) For a period of twelve (12) months after termination of the Employee’s employment with the Company or its affiliates for any reason, whether with or without cause, the Employee will not directly or
indirectly solicit or divert or accept business relating in any manner to Competing Products or to products, processes or services of the Company, from any of the customers or accounts of the Company with which the Employee had any contact as a
result of the Employee’s employment. 
 (ii) For a period of six (6) months after termination of the Employee’s
employment with the Company for any reason, whether with or without cause, the Employee will not (A) render services directly or indirectly, as an employee, consultant or otherwise, to any Competing Organization in connection with research on
or the acquisition, development, production, distribution, marketing or providing of any Competing Product, or (B) own any interest in any Competing Organization, other than less than 2% of the equity securities of a Competing Organization
which is publicly traded. 
 (c) Modification of Restrictions. The Employee agrees that the restrictions set forth in this Section are
fair and reasonable and are reasonably required for the protection of the interests of the Company. However, should an arbitrator or court nonetheless determine at a later date that such restrictions are unreasonable in light of the circumstances as
they then exist, then the Employee agrees that this Section shall be construed in such a manner as to impose on the Employee such restrictions as may then be reasonable and sufficient to assure Company of the intended benefits of this Section.

 15. PUBLICATIONS. The Employee agrees that Employee will in advance of publication provide the Company with copies of all writings and materials
which Employee proposes to publish during the term of the Employee’s employment and for two years thereafter. The Employee also agrees that Employee will, at the Company’s request, cause to be deleted from such writings and materials any
information disclosing Confidential Information. The Company’s good faith judgment in these matters will be final. At the Company’s sole discretion, the Employee will also, at the Company’s request, cause to be deleted any reference
whatsoever to the Company from such writings and materials. 
 16. EQUITABLE REMEDIES. The Employee agrees that it would be impossible or inadequate
to measure and calculate the Company’s damages from any breach of the covenants set forth in herein. Accordingly, at the sole discretion of the Company, the Employee agrees that if Employee breaches any of such Sections, the Company will have,
in addition to any other right or remedy available, the right to obtain an injunction from a court of competent jurisdiction restraining such breach or threatened breach and to specific performance of any such provision of this Agreement and, if it
prevails in such a proceeding, the right to recover from the Employee the costs and expenses thereof, including reasonable attorneys’ fees. 
 17.
REPRESENTATIONS AND WARRANTIES OF EMPLOYEE. The Employee represents and warrants as follows: (i) that the Employee has no obligations, legal or otherwise, inconsistent with the terms of this Agreement or with the Employee’s undertaking
a relationship with the Company; and (ii) that Employee has not entered into, nor will Employee enter into, any agreement (whether oral or written) 

 
in conflict with this Agreement. 
 18. MISCELLANEOUS.

 (a) Entire Agreement. This Agreement contains the entire understanding of the parties with respect to the subject matter. It may
not be changed orally but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought. 
 (b) No Waiver. The failure of either party to insist on strict compliance with the terms of this agreement in any instance or instances will not
be deemed a waiver of any such term of this Agreement or of that party’s right to require strict compliance with the terms of this Agreement in any other instance. 
 (c) Successors and Assigns. This Agreement shall be binding on and inure to the benefit of the successors in interest of the parties, including, in the case of the Employee, the Employee’s heirs, executors
and estate. The Employee may not assign the Employee’s obligations under this Agreement. The Company may not assign its obligations under this Agreement, except with the prior written consent of the Employee. 
 (d) Notices. Any notices or other communications provided for hereunder may be made by telecopier, first class mail or express courier services
provided that the same are addressed to the party required to be notified at its address first written above, or such other address as may hereafter be established for notices, and any notices or other communications sent by first class mail shall
be considered to have been made when posted. The parties telecopier numbers are as follows: Company—(617) 928-3450; Employee – 480-706-3701. Either party may change such addresses from time to time by providing written notice in the manner
set forth above. 
 (e) Severability. If any term or condition of this Agreement shall be invalid or unenforceable to any extent or in any
application, then the remainder of this Agreement, and such term or condition except to such extent or in such application, shall not be affected thereby, and each and every term and condition of this Agreement shall be valid and enforceable to the
fullest extent and in the broadest application permitted by law. 
 (f) Captions; Gender Captions of Sections herein are for
convenience only and are not intended to cover all matters therein. Any pronoun or other gender-linked term shall in each case refer, as applicable, to the masculine, feminine or neuter. Any defined term shall include it singular or plural form or
other part of speech. 
 (g) Governing Law. This Agreement shall be construed and enforced in accordance with the laws of The
Commonwealth of Massachusetts without giving effect to its principles on conflict of laws. 
  

							
	EMPLOYER:	 		 	
			
	PRO-PHARMACEUTICALS, INC.	 		 	
				
	By:	 	 David Platt
	 		 	Date: December 19, 2007
		 	David Platt, Ph.D.	 		 	
		 	Chairman of the Board	 		 	

							
	AGREED TO AND ACCEPTED	 		 	
			
	EMPLOYEE:	 		 	
				
	By:	 	 /s/ Theodore D. Zucconi
	 		 	Date: December 19, 2007
		 	Theodore D. Zucconi, Ph.D.	 		 	

 Exhibit A 
 List of Prior Inventions 
 and Original Works of Authorship 
  

					
	 Title
	 	 Date
	 	 Identifying
 Number or
 Brief Description

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00134-of-00352.parquet"}]]